References
Robak P, Jesionek-Kupnicka D, Kupnicki P, Polliack A, Robak T. 2020. Bone lesions in hairy cell leukemia: diagnosis and treatment. Eur J Haematol ; 105(6): 682-691
Maitre E, Cornet E, Troussard X. 2019. Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment. Am J Hematol ; 94: 1413-1422
Parry-Jones N, Joshi A, Forconi F, Dearden C, BSH guidelines committee. 2020. Guidelines for diagnosis and management of hairy cell leukemia (HCL) and hairy cell variant (HCL-V). Br J Haematol ; 191(5): 730-737
Tadmor T, Polliack A. 2015. Hairy cell leukemia: uncommon clinical features, unusual sites of involvement and some rare associations.Best Pract Res Clin Haematol ; 28(4): 193-199
Pattnaik SA, Padhi S, Chhabra G, Panigrahi MK, Das PK, Bhola RK, Mishra S. 2020. Atypical presentation of hairy cell leukemia: a report and comprehensive review. Blood Res ; 55 (2): 123-127
Yonal-Hindilerden I, Hindilerden F, Bulut-Dereli S, Yıldız E, Dogan IO, Nalcaci M. 2015. Hairy cell leukemia presenting with isolated skeletal involvement successfully treated by radiation therapy and cladribine: a case report and review of the literature. Case Rep Hematol ; 2015: 803-921
Rosen DS, Smith S, Gurbuxani S, Yamini B. 2008. Extranodal hairy cell leukemia presenting in the lumbar spine. J Neurosurg Spine ; 9(4): 374-376
Polliak A. 2002. Hairy cell leukemia: biology, clinical diagnosis, unusual manifestations and associated disorders. Rev Clin Expo Hematol ; 6(4): 366-388
Bouroncle BA, Wiseman BK, Doan CA. 1958. Leukemic reticuloendotheliosis.Blood ; 13:609-630
Rhyner K, Streuli R, Kistler GS. 1977. Hairy-cell leukemia with osteolytic bone changes. Schweizerische Medizinische Wochenschrift ; 107(25): 863-871
Lembersky BC, Ratain MJ, Golomb HM. 1988. Skeletal complications in hairy cell leukemia: diagnosis and therapy. J Clin Oncol ; 6(8): 1280-1284
Matutes E, Catovsky D. 1994. The value of scoring systems for the diagnosis of biphenotypic leukemia and mature B-cell disorders.Leuk Lymphoma ; 13 Suppl 1: 11-14
Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells VA, Sportoletti P, Pettirossi V, Mannucci R, Elliott O, Liso A, Ambrosetti A, Pulsoni A, Forconi F, Trentin L, Semenzato G, Inghirami G, Capponi M, Di Raimondo F, Patti C, Arcaini L, Musto P, Pileri S, Haferlach C, Schnittger S, Pizzolo G, Foà R, Farinelli L, Haferlach T, Pasqualucci L, Rabadan R, Falini B. 2011. BRAF mutations in hairy-cell leukemia. N Engl J Med ; 364 (24): 2305-2315.
Notarfranchi L, Russo F, Re F, Mancini C, Martella E, Falini B, Aversa F, Tiacci E. 2019. Hairy cell leukemia mimicking multiple myeloma. Lancet Oncology; e187
Doma A, Skerget M, Zagar I. 2019. 18F-FDG PET/CT for staging and evaluation of therapy in a patient with unusual hairy cell leukemia presentation. Clin Nucl Med ; 44(7): e458-e460.
Wang L, Tadros AS, Hoh CK, Wang HY. 2016. CD-10 positive hairy cell leukemia involving multiple deep lymph nodes. Clin Lymphoma Myeloma Leuk ; 16(5): e51-53
Robak P, Jesionek-Kupnicka D, Kupnicki P, Polliack A, Robak T. 2021. Multifocal osteolytic lesions in hairy cell leukemia - the importance of PET/CT in diagnosis and assessment. Ann Hematol ; 100(6): 1641-1645.
Spedini P, Tajana M, Bergonzi C. 2000. Unusual presentation of hairy cell leukemia. Haematologica ; 85(5): 548
Filippi AR, Franco P, Marinone C, Tarella C, Ricardi U. 2007. Treatment options in skeletal localizations of hairy cell leukemia: a systematic review on the role of radiation therapy. Am J Hematol ; 82(11): 1017-1021
Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B. 2017. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood ; 129(5): 553-560.
Else M, Dearden CE, Matutes E, Garcia-Talavera J, Rohatiner AZ, Johnson SA, O’Connor NT, Haynes A, Osuji N, Forconi F, Lauria F, Catovsky D. 2009. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol ; 145(6): 733-740.
Sigal DS, Sharpe R, Burian C, Saven A. 2010. Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood ; 115(10): 1893-1896.
Chihara D, Kantarjian H, O’Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Poku R, Jain P, Thompson P, Brandt M, Luthra R, Burger J, Keating M, Ravandi F. 2016. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol ; 174(5): 760-766.
Else M, Dearden CE, Matutes E, Forconi F, Lauria F, Ahmad H, Kelly S, Liyanage A, Ratnayake V, Shankari J, Whalley I, Catovsky D. 2011. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. Leuk Lymphoma ; 52 Suppl 2: 75-78.
Chihara D, Arons E, Stetler-Stevenson M, Yuan CM, Wang HW, Zhou H, Raffeld M, Xi L, Steinberg SM, Feurtado J, James L, Wilson W, Braylan RC, Calvo KR, Maric I, Dulau-Florea A, Kreitman RJ. 2020. Randomized phase II study of first-line cladribine with concurrent or delayed rituximab in patients with hairy cell leukemia. J Clin Oncol ; 38(14): 1527-1538
Figure 1. 18F-FDG PET/CT at diagnosis (A) and two months after treatment including cladribine and rituximab (R) (B).
A: PET scan at diagnosis revealing multiple hypermetabolic lesions: vertebral body of C3, right pedicle of T3, left vertebral hemicorps of T4, pedicle junction and left blade of T8, left acromion, bone lysis both of humeral heads, the two cotyls, coccygeal region, left internal tibial plateau and both femoral heads, femoral necks, per-trochanteric regions, great trochanters, femoral diaphysis. B: follow-up PET-scan 8 weeks after immuno-chemotherapy demonstrating metabolic response with decreased uptake of the multiple metastatic lesions.